ATE302205T1 - Thieno- und furopyrimidin derivate als a2a- rezeptor antagonisten - Google Patents

Thieno- und furopyrimidin derivate als a2a- rezeptor antagonisten

Info

Publication number
ATE302205T1
ATE302205T1 AT00940670T AT00940670T ATE302205T1 AT E302205 T1 ATE302205 T1 AT E302205T1 AT 00940670 T AT00940670 T AT 00940670T AT 00940670 T AT00940670 T AT 00940670T AT E302205 T1 ATE302205 T1 AT E302205T1
Authority
AT
Austria
Prior art keywords
thieno
receptor antagonists
furopyrimidine derivatives
furopyrimidine
derivatives
Prior art date
Application number
AT00940670T
Other languages
German (de)
English (en)
Inventor
Roger John Gillespie
Paul Richard Giles
Joanne Lerpiniere
Claire Elizabeth Dawson
David Bebbington
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Application granted granted Critical
Publication of ATE302205T1 publication Critical patent/ATE302205T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00940670T 1999-07-01 2000-06-30 Thieno- und furopyrimidin derivate als a2a- rezeptor antagonisten ATE302205T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915437.9A GB9915437D0 (en) 1999-07-01 1999-07-01 Chemical compounds III
PCT/GB2000/002517 WO2001002409A1 (en) 1999-07-01 2000-06-30 Thieno- and furopyrimidine derivatives as a2a-receptor antagonists

Publications (1)

Publication Number Publication Date
ATE302205T1 true ATE302205T1 (de) 2005-09-15

Family

ID=10856458

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00940670T ATE302205T1 (de) 1999-07-01 2000-06-30 Thieno- und furopyrimidin derivate als a2a- rezeptor antagonisten

Country Status (9)

Country Link
US (1) US6787541B1 (https=)
EP (1) EP1192164B1 (https=)
JP (1) JP4346269B2 (https=)
AT (1) ATE302205T1 (https=)
AU (1) AU5557800A (https=)
CA (1) CA2370344C (https=)
DE (1) DE60022042T2 (https=)
GB (1) GB9915437D0 (https=)
WO (1) WO2001002409A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202279B1 (en) 1998-02-11 2007-04-10 Georgetown University Cyclic dipeptides and azetidinone compounds and their use in treating CNS injury and neurodegenerative disorders
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
GB0100623D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100620D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical cokpounds V
US6903109B2 (en) * 2001-04-18 2005-06-07 Ortho-Muniel Pharmaceutical, Inc. Arylindenopyridines and related therapeutic and prophylactic methods
US6958328B2 (en) * 2001-04-18 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc Arylindenopyridines and related therapeutic and prophylactic methods
US20050239782A1 (en) * 2001-04-18 2005-10-27 Heintzelman Geoffrey R Arylindenopyridines and related therapeutic and prophylactic methods
ITRM20010465A1 (it) * 2001-07-31 2003-01-31 Sigma Tau Ind Farmaceuti Derivati della triazolil-imidazopiridina e delle triazolilpurine utili come ligandi del recettore a2a dell'adenosina e loro uso come medicam
KR101098209B1 (ko) * 2002-01-28 2011-12-23 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법
US20040127510A1 (en) * 2002-04-16 2004-07-01 Heintzelman Geoffrey R. Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
JP2005533109A (ja) * 2002-07-11 2005-11-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン 高増殖性障害の処置のためのフロピリジン及びフロピリミジン誘導体
DE60333762D1 (de) 2002-08-23 2010-09-23 Novartis Vaccines & Diagnostic Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
AR044743A1 (es) * 2002-09-26 2005-10-05 Nihon Nohyaku Co Ltd Herbicida, metodo de emplearlo, derivados de tienopirimidina sustituida,compuestos intermediarios, y procedimientos que se utilizan para producirlos,
TWI331036B (en) * 2002-12-19 2010-10-01 Schering Corp Adenosine a2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
WO2004092170A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
WO2004092177A1 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
WO2004092173A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. A2a adenosine receptor antagonists
WO2004092172A2 (en) * 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosin e receptor antagonists
US20080070932A1 (en) * 2003-04-09 2008-03-20 Chi Vu Triazolo[ 1,5-A] Pyrimidines And Pyrazolo[ 1,5-A] Pyrimidines And Methods Of Making And Using The Same
US7923448B2 (en) * 2003-11-03 2011-04-12 Cornell Research Foundation, Inc. Purine receptor inhibition as a therapeutic strategy in spinal cord and brain
WO2005080377A1 (ja) * 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
AU2005302448B2 (en) 2004-10-29 2012-07-19 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
US7674822B2 (en) 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
US7560544B2 (en) * 2004-12-17 2009-07-14 Anadys Pharmaceuticals, Inc. 3,5-Disubsitituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof
CN101212968B (zh) * 2004-12-17 2011-11-16 安那迪斯药品股份有限公司 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药
JP2008536866A (ja) * 2005-04-15 2008-09-11 ボード、オブ、トラスティーズ、オブ、ミシガン、ステイト、ユニバーシティ アミン作動性医薬組成物および方法
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
GB0718432D0 (en) * 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
GB0718434D0 (en) 2007-09-21 2007-10-31 Vernalis R&D Ltd New chemical compounds
WO2010008775A1 (en) * 2008-06-23 2010-01-21 Ligand Pharmaceuticals Inc. Aminopyridopyrazinone derivatives for treating neurodegenerative diseases
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
US20100093722A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent HETEROARYL AND PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093723A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent HETEROCYCLYL AND CYCLOALKYL SUBSTITUTED THIENO[2,3 d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093721A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093763A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
AU2010222289B2 (en) 2009-03-13 2013-07-11 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
WO2011133696A2 (en) 2010-04-20 2011-10-27 Regents Of The University Of Minnesota Methods of suppressing atherosclerosis
CN102408433B (zh) * 2011-10-20 2014-04-09 天津药物研究院 含嘧啶的肟类化合物、其制备方法和用途
CN102503953B (zh) * 2011-10-20 2014-02-19 天津药物研究院 肟类化合物
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
JP2020532541A (ja) * 2017-08-31 2020-11-12 コーバス・ファーマシューティカルズ・インコーポレイテッド アデノシンａ２ｂ受容体およびアデノシンａ２ａ受容体を調節するための化合物および方法
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders
WO2025160538A1 (en) * 2024-01-26 2025-07-31 The Board Of Regents Of The University Of Texas System Compositions and methods for treating hair graying and loss associated with aging

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842178B1 (en) 1995-07-28 2001-03-28 Abbott Laboratories Furopyridine, thienopyridine, pyrrolopyridine and related pyrimidine, pyridazine and triazine compounds useful in controlling chemical synaptic transmission
EP0975345A1 (en) 1997-11-26 2000-02-02 Cerebrus Pharmaceuticals Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
AU1688599A (en) 1998-01-05 1999-07-26 Eisai Co. Ltd. Purine derivatives and adenosine a2 receptor antagonists serving as preventives/remedies for diabetes
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
GB9819384D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9819382D0 (en) 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds I
US6841549B1 (en) 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus

Also Published As

Publication number Publication date
EP1192164A1 (en) 2002-04-03
AU5557800A (en) 2001-01-22
JP2003503504A (ja) 2003-01-28
JP4346269B2 (ja) 2009-10-21
CA2370344A1 (en) 2001-01-11
CA2370344C (en) 2010-09-07
DE60022042D1 (de) 2005-09-22
GB9915437D0 (en) 1999-09-01
EP1192164B1 (en) 2005-08-17
WO2001002409A1 (en) 2001-01-11
DE60022042T2 (de) 2006-06-29
US6787541B1 (en) 2004-09-07

Similar Documents

Publication Publication Date Title
ATE302205T1 (de) Thieno- und furopyrimidin derivate als a2a- rezeptor antagonisten
TR200000333T2 (tr) Y alıcı antagonistleri olarak 4-aminopirol (3,2-d) pirimidinler.
DE69415614D1 (de) N-acylierte trizyklische Azaheteroringe verwendbar als Vasopressin-Antagonisten
BR9807872A (pt) AtropisÈmeros de 3-aril-4(3h)-quinazolinonas e seu uso como antagonistas de receptor ampa
DE69618231D1 (de) TETRAHYDROIMIDAZOPYRIDOINDOLDIONE ALS cGMP SPEZIFISCHE PDE HEMMER
AU2003301020A8 (en) Isoquinolinone derivatives and their use as therapeutic agents
BR0007864A (pt) Composto, e, uso de um composto
DE60206756D1 (de) Purin derivate als a2b adenosin rezeptor antagonisten
NO20022683L (no) Ureaforbindelser med muskarinisk reseptor-antagonistaktivitet
ES2031513T3 (es) Quinazolindionas y piridopirimidinadionas.
MX2007003329A (es) Derivados heterociclicos y biciclicos y su uso como inhibidores de estearoil-coa-desaturasa (scd).
NO965125L (no) Heterosykliske forbindelser med tachykininreseptor-antagonistaktivitet, deres fremstilling og anvendelse
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
AU1816901A (en) Benzimidazole compounds having nociceptin receptor affinity
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
MXPA03009185A (es) Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson.
BR9809047A (pt) Derivados de isoquinolina substituìda e o uso dos mesmos como anticonvulsivantes
TR200000786T2 (tr) Vitronektin reseptör antagonisti
TR200002580T2 (tr) Hücre çoğalmasının engellenmesinde kullanılan ikameli bisindolimaleimitler
MXPA02012470A (es) Inhibidores de fosfodiesterasa especificos para gmp ciclico.
ATE263166T1 (de) Neue benzoxazole mit pde-hemmender wirkung
TR200101654T2 (tr) Vitronektin resept”r antagonistleri
DE69812010D1 (de) 4-Aminopyrrole (3,2-d) Pyrimidinen als Antagonisten des Neuropeptide Y Receptors
BRPI0409505A (pt) compostos como antagonistas do receptor crf1
DE60219788D1 (de) Tetrazyklische verbindungen als pde5-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties